Overall survival (OS) was defined as the time from the initiation of induction therapy to death from any cause; those alive or lost to follow-up were censored at the date last known alive.
The time from the initiation of IFX-induction therapy due to UC flare-up was longer in the partial-responders (P = 0.0255) or non-responders (P = 0.0072) vs responders; 107 days, 101 days and 38 days, respectively.
The time from induction of anesthesia until the experimental start point was approximately one hour in all animals and included the preparatory surgery and the preparation of the bacterial inoculum (Fig. 1).
Furthermore there was no significant relation between laryngeal mask cuff pressure and age (r = 0.129), body mass index (r = -0.015), type of surgery (r = -0.177), or the time from induction of anaesthesia to when the cuff pressure was determined (r = -0.074).
There was no significant relation between tracheal tube cuff pressure and age (r = 0.028), body mass index (r = 0.245), type of surgery (r = -0.001), or the time from induction of anaesthesia to determination of the cuff pressure (r = -0.168).
This property facilitates that fundamental axiom of RSI, which is that the time from induction of anesthesia to endotracheal intubation with a cuffed endotracheal tube, the airway's period of vulnerability to aspiration risk, should be as short as possible.
There was no association between cuff pressure and age, body mass index, type of surgery, or time from induction of anaesthesia to the time the cuff pressure was measured.
Time to progression (TTP) was defined as the time from the start of induction therapy until first progression or death due to PD. Survival was determined from the start of induction therapy to death from any cause.
The median time from induction of anaesthesia to first hydrocortisone dose for all 87 patients was 11 hours, and the median time from commencing noradrenaline to first steroid dose was 9 hours.
Follow-up time was defined as the time from the date of induction therapy to the date of death or last clinical follow-up.
